John Newman
Analyst
Canaccord Genuity
Equibles does not estimate personal net worth.
About John Newman
John Newman is recorded as Analyst at Canaccord Genuity. John Newman has spoken on 3 earnings calls and 4 other investor events across 6 companies, most recently for Tango Therapeutics, Inc. on October 23, 2026. Those appearances were for Delcath Systems, Inc. (DCTH), Tango Therapeutics, Inc. (TNGX), Candel Therapeutics, Inc. (CADL), TuHURA Biosciences, Inc. (HURA), Adicet Bio, Inc. (ACET) and 1 other company. The companies whose calls John Newman spoke on are classified in the Healthcare sector.
John Newman on recent calls
“And let me add my congrats on the really strong and impressive data here. Definitely, as Eric said, a big benefit for pancreatic cancer patients.”
“Good afternoon, everyone, and thank you for joining us at the 46th Annual Canicor Genuity Growth Conference here in sunny Boston today. I'm John Newman. I'm one of the biotech analysts here at the firm.”
“Thanks for joining us at the 46th Annual Canon Core Genuity Growth Conference here in Boston. I'm John Newman, one of the biotech analysts here at the firm. Very excited to have Tahura with us today and the CEO, Jim Bianco.”
“Good morning, everybody, and thank you very much for joining us at the 46th Annual Canicorge Unuity Growth Conference. I'm John Newman, one of the senior biotech analysts here at the firm.”
“So I'm curious as to how much of the increased guidance for the year could be related to better uptake due to the Chopin data. I'm also wondering if you can discuss your enrollment expectations for both colorectal and the breast cancer studies.”
Affiliation history
-
Canaccord Genuity
Analyst
Transcript header (unverified)
Current
Company network
Adicet Bio, Inc.
ACET
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-08-11
View calls and events